BioXcel Therapeutics Posts Strong Q4 Performance with Beating GAAP EPS Expectations
Tuesday, 12 March 2024, 11:02
BioXcel Therapeutics Financial Results
The recent press release from BioXcel Therapeutics (BTAI) unveiled its Q4 financial performance.
Key Highlights:
- GAAP EPS: -$0.76 (beat by $0.15)
- Revenue: $0.38M (+58.3% Y/Y, missed by $0.36M)
- Cash Reserves: $65.2 million
Despite the revenue miss, the company's strong cash position provides stability and growth opportunities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.